Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial
Stephan Windecker, Patrick W. Serruys, Simon Wandel, Paweł Buszman, Stanisław Trznadel, Axel Linke, Karsten Lenk, Thomas Ischinger, Volker Klauß, Franz R. Eberli, Roberto Corti, William Wijns, Marie‐Claude Morice, Carlo Di Mario, Simon Davies, Robert‐Jan van Geuns, Pedro Eerdmans, Gerrit-Anne van Es, Bernhard Meier, Peter Jüni (2008). Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. The Lancet, 372(9644), pp. 1163-1173, DOI: 10.1016/s0140-6736(08)61244-1.
Article403 days agoImproved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery Disease
Patrick W. Serruys, Vasim Farooq, Bindu Kalesan, Ton de Vries, Paweł Buszman, Axel Linke, Thomas Ischinger, Volker Klauß, Franz R. Eberli, William Wijns, Marie Claude Morice, Carlo Di Mario, Roberto Corti, Diethmar Antoni, Hae Young Sohn, Pedro Eerdmans, Tessa Rademaker‐Havinga, Gerrit‐Anne van Es, Bernhard Meier, Peter Jüni, Stephan Windecker (2013). Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery Disease. КАРДИОЛОГИЯ УЗБЕКИСТАНА, 6(8), pp. 777-789, DOI: 10.1016/j.jcin.2013.04.011.
Article403 days agoValue of the SYNTAX Score for Risk Assessment in the All-Comers Population of the Randomized Multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) Trial
Joanna J. Wykrzykowska, Scot Garg, Chrysafios Girasis, Ton de Vries, Marie-Angèle Morel, Gerrit-Anne van Es, Paweł Buszman, Axel Linke, Thomas Ischinger, Volker Klauß, Roberto Corti, Franz R. Eberli, William Wijns, Marie‐Claude Morice, Carlo Di Mario, Robert‐Jan van Geuns, Peter Jüni, Stephan Windecker, Patrick W. Serruys (2010). Value of the SYNTAX Score for Risk Assessment in the All-Comers Population of the Randomized Multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) Trial. Journal of the American College of Cardiology, 56(4), pp. 272-277, DOI: 10.1016/j.jacc.2010.03.044.
Article403 days agoValue of Age, Creatinine, and Ejection Fraction (ACEF Score) in Assessing Risk in Patients Undergoing Percutaneous Coronary Interventions in the ‘All-Comers' LEADERS Trial
Joanna J. Wykrzykowska, Scot Garg, Yoshinobu Onuma, Ton de Vries, Dick Goedhart, Marie-Angèle Morel, Gerrit‐Anne van Es, Paweł Buszman, Axel Linke, Thomas Ischinger, Volker Klauß, Roberto Corti, Franz R. Eberli, William Wijns, Marie‐Claude Morice, Carlo Di Mario, Robert‐Jan van Geuns, Peter Jüni, Stephan Windecker, Patrick W. Serruys (2011). Value of Age, Creatinine, and Ejection Fraction (ACEF Score) in Assessing Risk in Patients Undergoing Percutaneous Coronary Interventions in the ‘All-Comers' LEADERS Trial. Circulation Cardiovascular Interventions, 4(1), pp. 47-56, DOI: 10.1161/circinterventions.110.958389.
Article403 days agoFirst generation versus second generation drug‐eluting stents for the treatment of bifurcations: 5‐year follow‐up of the <scp>LEADERS</scp> all‐comers randomized trial
Maik J. Grundeken, Joanna J. Wykrzykowska, Yuki Ishibashi, Scot Garg, Ton de Vries, Héctor M. García‐García, Yoshinobu Onuma, Robbert J. de Winter, Paweł Buszman, Axel Linke, Thomas Ischinger, Volker Klauß, Franz R. Eberli, Roberto Corti, William Wijns, Marie‐Claude Morice, Carlo Di Mario, Bernhard Meier, Peter Jüni, Ashkan Yazdani, Samuel Copt, Stephan Windecker, Patrick W. Serruys (2015). First generation versus second generation drug‐eluting stents for the treatment of bifurcations: 5‐year follow‐up of the <scp>LEADERS</scp> all‐comers randomized trial. Catheterization and Cardiovascular Interventions, 87(7), DOI: 10.1002/ccd.26344.
Article403 days ago